ClinicalTrials.gg
CompletedNCT06812117Updated Oct 14, 2026

A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)

An observational study in Diabetic Peripheral Neuropathic Pain, sponsored by Daiichi Sankyo. Completed at 43 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Daiichi Sankyo · Observational

How we know

Updated Oct 14, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
721
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Neuralgia with a site in China — 17 open to participants now, 17 under way, 1 of them phase 3. Neuralgia · China.

Enrollment
3rd of 10
721 · median 300
Started
2025
with 6 others
Observational
10 of 41
4 open now
Registered
29th of 41
by date
Lead sponsor
2 of 41
Daiichi Sankyo

Among the 41 studies in Neuralgia with a site in China, this one is the 3rd largest by enrollment of the 10 observational ones that give a count, is one of 7 that started in 2025, is one of 10 observational ones, and was the 29th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

17 of the 41 studies in Neuralgia with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Neuralgia with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the safety and effectiveness of mirogabalin in adult patients with diabetic peripheral neuropathic pain (DPNP) in real-world clinical practice setting in China.

Read the detailed description

Mirogabalin has been approved in China for the treatment of DPNP. Although there is evidence of the safety and efficacy of mirogabalin, there is a lack of real-world evidence on its safety and effectiveness to inform decision-making among a more diverse patient population in real-world clinical practice, such as patients with moderate or severe renal impairment; patients with more complications, comorbidities, and treatments; and patients with different severity of pain.

This study aims to collect safety and effectiveness data to guide physicians in the clinical use of mirogabalin for the treatment of patients with DPNP in the real-world clinical practice setting.

03

Conditions studied

  • Diabetic Peripheral Neuropathic Pain

Browse trials for

Keywords

  • Diabetic peripheral neuropathic pain
  • Real-world evidence
  • Mirogabalin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Eligible patients diagnosed with DPNP and newly treated with mirogabalin will be consecutively enrolled in this study and followed up until the end of 15-week observation period, the end of 1-week observation period after the discontinuation of mirogabalin, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first, to collect and evaluate patients' outcomes.

Eligibility criteria

Inclusion Criteria:

Patients must meet all the following criteria to be eligible for this study.

  1. Age ≥ 18 years at the time of form (ICF) signed.
  2. Patients diagnosed with DPNP (defined as patients diagnosed with type 1 or type 2 diabetes and painful distal symmetric polyneuropathy).
  3. Patients with a pain scale of visual analog scale (VAS( ≥ 40 mm on the day of ICF signed.
  4. Patients who are mirogabalin naïve prior to ICF signed and planned to initiate mirogabalin treatment.
  5. Patients who are able to give signed ICF for study participation and willing to provide access to previous and future medical information.

Patients who meet any of the following criteria will be excluded from this study.

  1. Patients who have other severe pain unrelated to DPN at baseline, which may confound the assessment of DPNP.
  2. Patients who previously received pregabalin ≥ 300 mg/day or gabapentin ≥ 1200 mg/day to treat DPNP and declared lack of effectiveness.
  3. Patients who received pregabalin, gabapentin, crisugabalin, or any other DPNP analgesic medications* within 7 days prior to ICF signed.

    *Other DPNP analgesic medication includes TCAs (amitriptyline, nortriptyline), SNRIs (duloxetine, venlafaxine), antiepileptics (carbamazepine), opioids (tapentadol, tramadol).

  4. Patients with major psychiatric disorders (depression, Alzheimer disease, Parkinson disease, mania, bipolar disorder, psychosis, or schizophrenia, etc.) at baseline.
  5. Patients with for mirogabalin treatment according to China package insert of mirogabalin.
  6. Patients with simultaneous participation in any interventional clinical study.
  7. Female patients at the status of pregnancy, potential pregnancy, or breast feeding.
  8. Patients who have been judged by the investigator to be unsuitable to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
721 participants (actual)
Patient registry
No

Groups and cohorts

  • Diabetic peripheral neuropathic pain (DPNP)

    Patients diagnosed with DPNP and newly treated with mirogabalin.

    Other: No Drug

Interventions

  • OtherNo Drug

    This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on mirogabalin will be enrolled in this study.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with any treatment related adverse events (TRAEs)

    An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Baseline to Week 14

Secondary outcomes

  1. Time-to-onset of somnolence, dizziness, weight gain, and peripheral edema

    For time-to-event variables, the median time, Q1 and Q3 as well as 95% CI will be estimated.

    Time frame: Baseline to Week 14

  2. Symptom duration of somnolence, dizziness, weight gain, and peripheral edema

    For time-to-event variables, the median time, Q1 and Q3 as well as 95% CI will be estimated.

    Time frame: Baseline to Week 14

  3. Proportion of participants with TEAEs, serious TEAEs, TRAEs leading to study treatment discontinuation

    An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Baseline to Week 14

  4. Change from baseline in VAS pain

    The VAS is used for the participant to rate average pain intensity of past 24 hours on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain. Reductions in VAS pain scores indicate better clinical outcome.

    Time frame: Week 14

  5. Proportion of participants achieving 30% and 50% pain relief (reduction in VAS score compared to baseline)

    The VAS is used for the participant to rate average pain intensity of past 24 hours on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain. Reductions in VAS pain scores indicate better clinical outcome.

    Time frame: Baseline to Week 14

  6. Time to achieve 30% pain relief or 50% pain relief (reduction in VAS score compared to baseline)

    The VAS is used for the participant to rate average pain intensity of past 24 hours on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain. Reductions in VAS pain scores indicate better clinical outcome.

    Time frame: Baseline to Week 14

  7. Change from baseline in Douleur Neuropathique 4 questions (DN4) score

    DN4 will be assessed by the investigator after ICF signed and prior to the first administration of mirogabalin as baseline, when participants return to the clinical site during treatment period of mirogabalin, and at the end of mirogabalin treatment. Each "yes" answer is assigned 1 point, and a total score is calculated. A score of 4 or higher indicates a higher likelihood of neuropathic pain (eg. worse clinical outcome), while a score below 3 suggests it is less likely (eg. better clinical outcome).

    Time frame: Week 14

  8. Patient Global Impression of Change (PGIC)

    Participants will provide a self-assessment using the 7-point scale via ePRO at the end of mirogabalin treatment: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse. Lower PGIC scores indicate better clinical outcome.

    Time frame: Week 14

  9. Change from baseline in EuroQol 5-Dimension 5-level (EQ-5D-5L)

    The self-administered EQ-5D-5L includes the EQ-5D and the EQ VAS. EQ-5D comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3-moderate problems, 4=severe problems and 5=extreme problems. The patient is asked to indicate his/her health state in each of the five dimensions, resulting in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. Lower 5-digit numbers indicates better clinical outcome (ie, health state). The EQ VAS records the patient's self-rated health on a vertical VAS where the endpoints are labelled '100 - The best health you can imagine' and '0 - The worst health you can imagine'. Higher EQ VAS scores indicate better clinical outcome/health.

    Time frame: Week 14

07

Study locations

43 sites
  • China-Japan friendship hospital
    Beijing, 100013, China
  • Xuanwu Hospital Capital Medical University
    Beijing, 100053, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Beijing Pinggu Hospital
    Beijing, 101200, China
  • Xiangya Hospital of Central South University
    Changsha, 410008, China
  • Chengdu First People's Hospital
    Chengdu, 610041, China
  • West China Hospital of Sichuan University
    Chengdu, 610041, China
  • Sichuan Provincial People's Hospital
    Chengdu, 610072, China
  • Chengdu Fifth People's Hospital
    Chengdu, 611130, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, 400010, China
  • The First People's Hospital Of Foshan
    Foshan, 528041, China
  • Shunde Hospital of southern Medical University
    Foshan, 528300, China
  • Fujian Medical University Union Hospital
    Fuzhou, 350001, China
  • Guangdong Provincial People's Hospital
    Guangzhou, 510000, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, 510080, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, 510515, China
  • The First Affiliated Hospital of Jinan University
    Guangzhou, 510632, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, 310009, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, 310025, China
  • The First Affiliated Hospital of Henan University of Science & Technology
    Henan, 471622, China
  • The First People's Hospital Of Yunnan
    Kunming, 650032, China
  • The Affiliated Hospital of Nanjing University Medical School
    Nanjing, 210008, China
  • The Fourth Affiliated Hospital of Nanjing Medical University
    Nanjing, 225300, China
  • Nanyang First People's Hospital
    Nanyang, 473000, China
  • The First Affiliated Hospital of Nanyang Medical College
    Nanyang, 473000, China
  • Pingxiang People's Hospital
    Pingxiang, 337005, China
  • Qingdao Municipal Hospital
    Qingdao, 266001, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, 266003, China
  • Renji Hospital, Shanghai Jiaotong University School Of Medicine
    Shanghai, 200001, China
  • Huadong Hospital
    Shanghai, 200040, China
  • Huashan Hospital Fudan University
    Shanghai, 200040, China
  • Shanghai Tenth People's Hospital
    Shanghai, 200080, China
  • ZhongShan Hospital Fudan University
    Shanghai, 20032, China
  • Shenzhen Nanshan People's Hospital
    Shenzhen, 518020, China
  • First Hospital of Shanxi Medical University
    Taiyuan, 030001, China
  • Taizhou People's Hospital
    Taizhou, 225300, China
  • The Second Hospital of Tianjin Medical University
    Tianjin, 300211, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, 325000, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, 430014, China
  • Wuhan Central Hospital
    Wuhan, 430014, China
  • Wuhan Third Hospital
    Wuhan, 430050, China
  • Wuxi People's Hospital
    Wuxi, 214028, China
  • Yibin Second People's Hospital
    Yibin, 644603, China
08

References and documents

Publications

  • Zhao L, Liu B, Chen H, Lu B, Wang W, Shi Y, Li M, Guo N, Fan B, Li X. Real-World Safety and Effectiveness of Mirogabalin in Chinese Adults with Diabetic Peripheral Neuropathic Pain: a Protocol of ReMIssion Study. Pain Ther. 2026 Jun;15(3):905-920. doi: 10.1007/s40122-026-00827-w. Epub 2026 Mar 18. PubMed 41849003 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Apr 2026, 14 months.

Of 88 observational studies under Neuralgia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's 14 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Jul 2026 → Apr 2026 and completion Jul 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2025
First posted
Feb 6, 2025
StartActual
Jan 24, 2025
Primary completionActual
Apr 9, 2026was Jul 2026
CompletionActual
Apr 9, 2026was Jul 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 14, 2026
Primary completion
Jul 24, 2026→Apr 9, 2026 (actual)
Oct 14, 2026
Study completion
Jul 24, 2026→Apr 9, 2026 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Active, not recruiting→Completed
    Primary completion Jul 24, 2026→Apr 9, 2026 (now actual)
    Study completion Jul 24, 2026→Apr 9, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06812117
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Feb 6, 2025
Start date
Jan 24, 2025
Primary completion
Apr 9, 2026
Completion
Apr 9, 2026
Last update
Oct 14, 2026

Study contacts

Project Manager
study director · Daiichi Sankyo Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion